Emgality (galcanezumab-gnlm) is a biologic prescription medicine specifically developed for the prevention of migraine and the treatment of episodic cluster headache in adults. It belongs to a class of drugs known as CGRP (calcitonin gene-related peptide) antagonists—humanized monoclonal antibodies that bind to and block the activity of CGRP, a protein that plays a key role in triggering migraine and cluster headache pain. By inhibiting CGRP, Emgality helps reduce the frequency and severity of headache attacks.

Emgality is administered once a month by subcutaneous injection under the skin, typically after an initial loading dose in migraine prevention. It is available in prefilled pens and syringes and can be self-administered after proper training. In migraine prevention, the first dose is often given as two injections, then one monthly dose thereafter. For episodic cluster headache, a series of injections is given at the start of a cluster period and continued monthly through the cluster phase.

Clinical studies have shown that Emgality can significantly reduce the number of monthly migraine days and decrease the frequency of cluster headache attacks compared with placebo. Like all medications, it may cause side effects—most commonly reactions at the injection site such as pain, redness, or itching. Serious allergic reactions are rare but possible. Emgality is only available with a doctor’s prescription and should be used under medical supervision.